No Stock Yet
KTTA Pasithea Therapeutics
0.3750.0000.00%
YOY
Do not show
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Financial Ratios
Efficiency Ratios TTM
Fixed Assets Turnover（T）
--
0.4073
--
0.0729
--
0.2233
--
0.7485
Total Asset Rate（T）
--
0.0074
--
0.0016
--
0.0011
--
0.0006
ROIC
--
-25.107%
--
-19.403%
--
-12.572%
--
-8.412%
ROE
--
-25.887%
--
-19.747%
--
-12.572%
--
-8.414%
ROA
--
-23.181%
--
-19.012%
--
-12.249%
--
-8.115%
Efficiency Ratios
Profitability Ratios TTM
Gross Margin
--
49.493%
--
-7.120%
--
-5.195%
--
-14.693%
Operating Margin
--
-4481.141%
--
-20601.139%
--
-22152.998%
--
-29925.727%
Net Margin
--
-3138.497%
--
-12124.061%
--
-11135.627%
--
-14430.494%
EBITDA Margin
--
-35.7345%
--
-150.4198%
--
-140.026%
--
-144.1797%
R & D Expense Ratio
--
0.000%
--
0.000%
--
0.000%
--
0.000%
Sales Expense Ratio
--
0.000%
--
0.000%
--
0.000%
--
0.000%
Administration Expense Rate
--
0.000%
--
0.000%
--
0.000%
--
0.000%
Financial Health Ratios
Long-Term Debt to Equity Ratio
--
1.548%
--
0.696%
--
--
--
--
Total Assets to Common Equity
-16.99%
106.026%
-47.63%
103.019%
-19.26%
102.203%
0.93%
103.695%
Debt to Asset Ratio
--
2.100%
--
0.893%
--
--
--
--
Current Ratio
-26.25%
29.3725
2,415.75%
51.1669
2,367.39%
117.4817
217.33%
119.1658
Quick Ratio
-28.09%
28.0045
3,932.12%
50.4573
2,494.88%
116.032
220.92%
118.4196
GrowthRatios
Growth Ratios
Currency Unit
USDUSDUSDUSD
FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.
Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.
The MOM data from the Quarterly report，MOM=(current period - last period)/last period *100%
Company Overview
More
CEO： Dr. Tiago Reis Marques
Market： NASDAQ
Listing Date： 09/15/2021
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist